News
Sacituzumab tirumotecan showed “promising efficacy” regardless of PD-L1 status, said study presenter Yongmei Yin, MD, PhD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results